Last updated: February 13, 2026
Overview
NDC 70000-0146 is the drug Sodium Oxybate (brand name: Xyrem), approved by the FDA for cataplexy and excessive daytime sleepiness associated with narcolepsy. It is marketed by Jazz Pharmaceuticals. The drug's unique efficacy and limited competition influence its market position and pricing trajectory.
Market Size and Demand Dynamics
Patient Population
- Estimated U.S. narcolepsy prevalence: 25,000 – 50,000 individuals.
- Cataplexy occurs in 70% of narcolepsy cases, making treatment of these symptoms a primary driver.
- Off-label use for disorders like alcohol dependence and fibromyalgia exists but remains limited.
Sales Data
- 2022: U.S. sales exceeded $1.2 billion.
- Growth rate: About 5% annually, driven by increased diagnosis and awareness.
- Market penetration: Approximately 80% of diagnosed patients receive treatment.
Competitive Landscape
- Other medications used off-label or for sleep disorders, but none replicate Sodium Oxybate's efficacy fully.
- Limited direct competition due to the drug's unique mechanism and FDA approval specificity.
Pricing Structure and Cost Considerations
Current Pricing
- Wholesale acquisition cost (WAC): Approximately $65 per gram.
- Typical dosing: 4.5 to 9 grams per night (divided doses).
- Monthly cost per patient: Ranges from $2,340 to $4,680, depending on dose and compliance.
Reimbursement Environment
- Most patients covered by commercial insurance, Medicaid, or Medicare.
- High reimbursement rates mitigate access barriers but introduce regulatory oversight to prevent misuse.
Manufacturing and Distribution
- The drug's formulation with a Schedule III classification influences manufacturing costs and security protocols.
- Production costs are estimated at a fraction of the retail price, giving Jazz Pharmaceuticals pricing power.
Regulatory and Patent Landscape
Patent Status
- Original patents expired around 2015.
- New formulations and delivery devices have patents extending into the mid-2020s.
- Orphan drug exclusivity for narcolepsy remains until at least 2025 in the U.S.
Regulatory Environment
- Ongoing strict controls due to potential misuse.
- The FDA continuously monitors labeling, safety, and prescribing practices.
Price Projection Analysis
Short-term Outlook (1-2 years)
- Stable pricing expected, supported by high demand, limited competition, and regulatory controls.
- Slight increases of 2-3% annually expected, reflecting inflation and rising healthcare costs.
Medium-term Outlook (3-5 years)
- Potential price plateau or slight decrease if new formulations or generics gain market approval.
- Patent cliffs post-2025 could stimulate generic entry, pressuring prices downward by 15-30%.
Long-term Outlook (beyond 5 years)
- Entry of generics or biosimilars likely reduces prices.
- Developments in alternative therapies could further impact demand and pricing.
Market Risks and Opportunities
Risks
- Regulatory actions on abuse potential could restrict access.
- Competition from investigational drugs or improved delivery systems.
- Policy changes impacting reimbursement rates.
Opportunities
- Expansion into other sleep and neurological disorders.
- Development of fixed-dose combinations.
- International expansion in markets with unmet needs.
Comparable Drug Price Trends
| Drug |
Market Size |
2022 Sales |
Patent Status |
Price Trends |
| Xyrem (Sodium Oxybate) |
~$1.2B |
$1.2B |
Patent until 2025 |
Slight annual growth, potential reduction post-patent expiry |
| Generic Sodium Oxybate (developing) |
Unknown |
Not available |
Pending approvals |
Likely to diminish branded prices by 15-30% after entry |
| Modafinil (for narcolepsy) |
~$0.6B |
$600M |
Patent expired |
Price has decreased substantially since patent expiration |
Key Takeaways
- The drug's market remains stable due to high demand and limited competition.
- Current pricing sustains significant revenue; minor annual increases are typical.
- The expiration of key patents and regulatory changes forecast potential price declines within 3-5 years.
- Competitive threats primarily come from generics and new therapeutic modalities.
- International markets offer growth opportunities, particularly where existing treatments are limited.
FAQs
1. Will the price of Sodium Oxybate decline after patent expiration?
Yes. The entry of generics typically leads to a 15-30% price reduction over 1-2 years post-patent expiry.
2. Are there upcoming regulatory risks that could impact pricing?
Regulatory agencies may impose restrictions on misuse or redress abuse risks, potentially affecting distribution and pricing structures.
3. How does insurance reimbursement influence the market?
High insurance coverage maintains access and supports stable sales, but policy changes might influence reimbursement rates in the future.
4. What is the potential impact of new therapies?
Emerging therapies targeting sleep disorders or narcolepsy pathways could substitute current treatments, impacting demand and pricing.
5. How do international markets compare in terms of pricing and access?
Pricing and access vary; some countries have generic versions earlier or restrict use, influencing global market dynamics.
Sources
[1] IQVIA, "Pharmaceutical Market Data" 2022.
[2] Jazz Pharmaceuticals, Financial Reports 2022.
[3] FDA, "Sodium Oxybate (Xyrem) Approval History."
[4] MarketWatch, "Narcolepsy Drugs Market Analysis," 2022.
